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Background: Despite the availability of evidence-based guidelines on venous thromboembolism (VTE) prevention
clinical audit and research reveals that hospitalised medical patients frequently receive suboptimal prophylaxis. The
aim of this study was to evaluate the acceptability, utility and clinical impact of an educational outreach visit (EOV)
on the provision of VTE prophylaxis to hospitalised medical patients in a 270 bed acute care private hospital in
metropolitan Australia.
Methods: The study used an uncontrolled before-and-after design with accompanying process evaluation. The
acceptability of the intervention to participants was measured with a post intervention survey; descriptive data on
resource use was collected as a measure of utility; and clinical impact (prophylaxis rate) was assessed by pre and
post intervention clinical audits. Doctors who admit >40 medical patients each year were targeted to receive the
intervention which consisted of a one-to-one educational visit on VTE prevention from a trained peer facilitator. The
EOV protocol was designed by a multidisciplinary group of healthcare professionals using social marketing theory.
Results: Nineteen (73%) of 26 eligible participants received an EOV. The majority (n = 16, 85%) felt the EOV was
effective or extremely effective at increasing their knowledge about VTE prophylaxis and 15 (78%) gave a verbal
commitment to provide evidence-based prophylaxis. The average length of each visit was 15 minutes (IQ range 15
to 20) and the average time spent arranging and conducting each visit was 92 minutes (IQ range 78 to 129). There
was a significant improvement in the proportion of medical patients receiving appropriate pharmacological VTE
prophylaxis following the intervention (54% to 70%, 16% improvement, 95% CI 5 to 26, p = 0.004).
Conclusions: EOV is effective at improving doctors’ provision of pharmacological VTE prophylaxis to hospitalised
medical patients. It was also found to be an acceptable implementation strategy by the majority of participants;
however, it was resource intensive requiring on average 92 minutes per visit.
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Venous thromboembolism (VTE) is a common and po-
tentially devastating complication of hospitalisation. Fail-
ure to provide appropriate VTE prophylaxis can result
in serious adverse outcomes including symptomatic deep
vein thrombosis (DVT) or pulmonary embolism (PE),
post-thrombotic syndrome, chronic pulmonary hyper-
tension, recurrent VTE, or fatal PE. Each year in the
United States there are an estimated one million cases of
VTE resulting in approximately 300,000 deaths annually
[1]. Together, the combined morbidity and mortality as-
sociated with this disease process result in an estimated
economic burden to the nation of $1.5 billion/year [2].
People who are hospitalised with acute medical illness
are particularly at risk of VTE. Without effective
prophylaxis 10-20% of medical patients will develop an
objectively diagnosed VTE which, in turn, has the poten-
tial to result in fatal PE. Within the acute patient popu-
lation, fatal PE accounts for 10% of all deaths making it
the single most preventable cause of hospital related
mortality [3]. Contrary to common held perceptions, a
significant proportion of these deaths occur in the med-
ical patient population. A retrospective evaluation of
6833 autopsies found that 80% of the fatal PEs occurred
in medical (nonsurgical) patients [4].
VTE in hospitalised medical patients is preventable;
evidence-based guidelines recommend the use of low
molecular weight heparin, low dose unfractionated hep-
arin, or fondaparinux for patients deemed to be at in-
creased risk of VTE [5,6]. Risk factors for VTE in
medical patients include active cancer, previous VTE, re-
duced mobility, known thrombophylic condition, in-
creased age, heart and/or respiratory failure, myocardial
infarction, ischaemia stroke, acute infection or rheuma-
tologic condition, obesity, and ongoing hormonal treat-
ment [5,6]. A number of tools have been developed and
validated to aid in the assessment of VTE risk and help
determine the onset, intensity, type, and duration of
recommended prophylaxis [7-9].
Despite the widespread availability of evidence-based
guidelines on VTE prevention hospitalised medical pa-
tients still receive suboptimal prophylaxis [10-13]. One
international study, the ENDORSE study, found that
only 40% of at risk medical patients (n = 37,356) were re-
ceiving the recommended prophylaxis [12,14]. Numer-
ous strategies to improve VTE prevention in hospitalised
patients have been studied with varying degrees of suc-
cess [15-19]. The evidence suggests that active imple-
mentation strategies that engage the target population
are more effective than passive strategies at changing
clinician behaviour and improving prophylaxis rates
[15,17,19].
An educational outreach visit (EOV) is an active im-
plementation strategy that entails a structured one-to-one educational visit conducted in the clinical setting of
the participant by a trained facilitator [20]. This inter-
vention is also known as university-based educational
detailing, academic detailing, and educational visiting
[21]. An EOV is based on social marketing theory. It re-
lies on the psychological principles of persuasion to in-
fluence clinician behaviour and promote evidence-based
practices [22]. A Cochrane systematic review of this im-
plementation strategy concluded that EOVs, alone or in
combination with other interventions, are consistently
effective at influencing prescribing practices [21]. There
have been few studies, however, examining the clinical
impact of EOVs on the provision of VTE prophylaxis to
medical patients and no previous studies on its accept-
ability or utility.
Methods
Objective
To evaluate the acceptability, utility and clinical impact
of an EOV on doctors’ provision of pharmacological
VTE prophylaxis to hospitalised medical patients.
Target population
The target population was doctors who regularly admit
medical (nonsurgical) patients to the study site. Regular
was defined as being in the top two quartiles of
admitters which equated to a minimum of 40 admissions
per year.
Setting
The study site is a 270 bed acute care private hospital in
Sydney, Australia. It provides services in all major fields
of medicine and surgery with the exception of obstetric
and paediatric care. The hospital has approximately
20,000 admissions annually, with approximately 30% ad-
mitted for acute medical illness. As is the case in most
private hospitals in Australia, patients are cared for by
consulting medical officers with minimal support from
junior medical staff.
Ethics
The study received ethics clearance from the St Vincent’s
Human Research Ethics Committee (File number 11/051).
Intervention
A vascular medicine physician with expertise in VTE
prevention was recruited to the role of EOV facilitator
and was responsible for arranging and conducting
each visit. The facilitator followed a strict protocol
which was collaboratively developed by a multidiscip-
linary team of healthcare professionals (see Table 1). A
Cochrane systematic review [21] and social marketing
literature [22-24] informed the development of the
protocol.
Table 1 Educational outreach visit protocol
EOV component Element
Planning the visit Contact the target population by email, phone, or in person
Negotiate a convenient time and location for the visit
Reconfirm arrangements prior to the visit
Discuss with the research team any recruitment difficulties
Setting the scene Ensure appropriate space for the discussion
Engage in small talk to place the participant at ease
Explain the purpose of the visit
Negotiate the session length (approximately 20 minutes)
Introduce the four key messages and identify participants specific needs
Building trust, credibility and likability Mention the key opinion leaders in support of the project
List the project’s academic and clinical affiliations
Highlight your own clinical expertise in the area
Attempt to uncover personal similarities between participant and yourself
Offer genuine praise where appropriate
Promoting two-sided communication Ask open ended questions
Use minimal encouragement techniques
Paraphrase and reflect on the participants comments
Anticipate and acknowledge controversial issues
Overcome any objections and handle challenging responses
Delivering key message(s) VTE is an important healthcare issue
Assess individual patient risk
Provide evidence-based VTE prophylaxis and patient education
Monitor and reassess each patient during their hospital stay
Wrapping up Reflect on the discussion
Reiterate the key message(s) discussed
Give the participant the printed resource material to keep
Gain commitment to provide evidence-based prophylaxis
Providing follow-up Follow-up via email, phone, or in person
Fulfil any commitments made during the visit
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ing on social marketing and persuasive communication
techniques in a two day workshop run by an independ-
ent not-for-profit organisation (the National Prescribing
Service) with extensive experience in the use of EOVs
for the promotion of the quality use of medicine in the
Australian healthcare system.
The multidisciplinary group also developed the con-
tent to be delivered by the facilitator during the EOV.
The content was limited to four key messages: 1) VTE is
an important healthcare issue which results in significant
mortality, morbidity and resource expenditure; 2) pa-
tients must have their risks assessed including clotting
risk, bleeding risk, and contraindications to prophylaxis;
3) patients must receive appropriate prophylaxis based
on their risk assessment; and 4) patients must be moni-
tored for signs of VTE or prophylaxis related adverseevents. A concise graphic educational resource was de-
veloped to accompany and reinforce the verbal message.
Two trial visits were conducted prior to the interven-
tion period to identify potential issues and familiarise
the facilitator with the protocol.
Outcome measures and data collection
Acceptability
Acceptability was measured with post intervention par-
ticipant and facilitator surveys. The participants’ survey
and self-addressed envelope were given to the partici-
pants by the facilitator following the EOV. The survey
contained eight questions in total; six questions related
to the doctor’s beliefs about the effectiveness of the EOV
at increasing knowledge and addressing concerns about
VTE prophylaxis for medical patients. The remaining
two questions asked participants how likely it was that
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future, and how likely it was that the intervention would
influence their clinical practice. The EOV facilitator was
also asked to complete a post intervention survey ap-
praising the participants’ level of interest, participation
and comprehension. All survey questions were answered
on a five point likert scale.
Utility
Descriptive data on the practical application and utility
of the intervention were recorded on a data collection
form by the EOV facilitator. The information included
the time and effort spent arranging the EOV, the time
spent conducting the EOV, the number of interruptions
and the time spent on them, the location of the EOV,
the facilitator’s self-assessed adherence to the elements
of the study protocol, and whether or not the participant
committed to provide evidence-based prophylaxis.
Clinical impact
Clinical impact was assessed by auditing the propor-
tion of medical patients receiving appropriate pharma-
cological VTE prophylaxis before and after the EOV
intervention. The audits were conducted using an
audit tool based on national VTE prevention guide-
lines [6]. A registered nurse trained in the use of
the tool conducted each audit with expert adjudica-
tion from a consultant vascular physician when re-
quired. VTE prophylaxis was deemed appropriate if it
conformed to the locally endorsed guideline with con-
sideration given to individual risk status and contrain-
dications. As per the guideline, patients were classified
as high-risk based on the presence of one or more
known risk factor (see Table 2). Contraindications to
pharmacological prophylaxis included active bleeding;
high risk of bleeding; severe hepatic disease; heparin
induced thrombocytopenia; or current anticoagulation.
The definition of appropriate includes prophylaxis pre-
scribed when indicated; and prophylaxis not prescribed
when contraindicated. The following exclusion criteria
were used for patient selection: Planned or prior (pre-
vious 30 days) surgery on that admission; admitted for
less than 24 hours; and inadequate documentation to
complete a risk assessment.
Sample size
The study was designed to detect a change in prescrib-
ing practice of 15% (from 50% to 65% appropriate
prophylaxis). This estimate of effect was based on two
previous studies which had used EOVs to improve VTE
prophylaxis in the acute care setting [25,26]. A total
sample size of 300 patients (150 pre and 150 post inter-
vention) was necessary to power the study at 80% with a
significance level of 5%.Data analysis
Data were entered into SPSS version 18 for analysis.
Categorical data were summarised as number and per-
centage and contiguous data were summarised as
median and interquartile (IQ) range. For comparisons
between groups, the T test, or Mann–Whitney U test,
was used for continuous variables (age, number of years
post registration) and the Chi-square test was used for
dichotomous variables (appropriate prophylaxis, risk
factors, sex, specialty unit, admitting specialty). The dif-
ference in pharmacological prophylaxis rates before and
after the intervention was calculated with 95% confi-
dence intervals. The p value for statistical significance
was set at <0.05.
Results
Characteristics of the target population
Of the 26 doctors who met the inclusion criteria 19
(73%) agreed to participate in the intervention and seven
(27%) declined or were unavailable. The demographic
characteristics of the target population are shown in
Table 3. The median age of the participants was 54 years
(IQ range 42–65) and their median number of years post
registration was 30 years (IQ range 18–41). Fifteen
(79%) were male and four (21%) female. The clinical spe-
cialties of the doctors were cardiology (n = 8, 42%); neur-
ology (n = 4, 21%); nephrology (n = 1, 5.3%); medical
oncology (n = 1, 5.3%); immunology/rheumatology (n =
2, 10%); thoracic medicine (n = 2, 10%); and gastroenter-
ology (n = 1, 5.3%). There was no statistical difference in
sex, number of years post registration, or specialty be-
tween doctors who received the intervention and those
who declined or were unavailable.
Characteristics of the audited patients
A total of 300 consecutive patients who met the inclu-
sion criteria were audited before (n = 150) and after (n =
150) the two month EOV intervention period. The
demographic characteristics of the audited patients are
summarised in Table 4. There were no statistical differ-
ences between the two groups in age, sex, admitting spe-
cialty, or risk profile. The mean age of the groups was
70.8 (SD 14.4) and 72.4 (SD 13.9) years respectively. The
majority of patients in both groups were admitted by a
cardiologist (n = 91, 60% and n = 90, 60%). There was no
significant difference in risk profile or contraindications
to prophylaxis between the two patient groups (Table 2).
The majority of patients were identified as being at a
high risk of VTE (84% in the pre intervention group and
77% in the post intervention group).
Acceptability
Table 5 depicts the results of the participant and facilita-
tor post intervention survey. Sixteen (94%) of the 17
Table 3 Characteristics of the target population
Characteristics Received the intervention (n = 19) Declined or unavailable (n = 7) P value
Age Median (IQ range) 54 (42–65) N/A
Years post registration 30 (18–41) 26 (23–33) 0.93*
Sex Number (%) 0.18^
Male 15 (79) 7 (100)
Female 4 (21) 0 (0)
Specialty 0.32^
Cardiology 8 (42) 3 (43)
Neurology 4 (21) 1 (14)
Nephrology 1 (5.3) 0 (0)
Medical oncology 1 (5.3) 0 (0)
Immunology/ rheumatology 2 (10) 0 (0)
Thoracic medicine 2 (10) 0 (0)
Gastroenterology 1 (5.3) 3 (43)
Percentages may not add up to 100 due to missing data. IQ Interquartile range; N/A not available; *Mann–Whitney U test; ^Chi-square.
Table 2 VTE risk factors & contraindications to prophylaxis
Risk factors & contraindications Pre intervention (n = 150) Post intervention (n = 150) P Value
High-risk of VTE 126 (84) 116 (77) 0.14^
Risk factors
Ischaemic stroke 7 (4.7) 3 (2) 0.19^
History of VTE 15 (10) 18 (12) 0.58^
Active cancer 4 (2.7) 4 (2.7) 1.0^
Decompensated heart failure 42 (28) 29 (19) 0.7^
Acute on chronic lung disease 10 (6.7) 10 (6.7) 1.0^
Age > 60 years and immobile 107 (71) 108 (72) 0.89^
Acute inflammatory disease 6 (4) 1 (0.7) 0.5^
Multiple additional risk factors 21 (14) 10 (6.7) 0.33^
Additional risk factors
Immobility (<60 years) 1 (0.7) 1 (0.7) 0.98^
Familial history of VTE 1 (0.7) 0 (0) 0.31^
Oestrogen therapy 2 (1.4) 1 (0.7) 0.55^
Obesity 10 (6.8) 7 (4.7) 0.43^
Thrombophilia 1 (0.7) 0 (0) 0.313^
Active inflammation 6 (4.1) 2 (1.4) 0.09^
Contraindications 48 (32) 49 (32.7) 0.15^
Active bleeding 5 (3.3) 5 (3.3) 1.0^
High risk of bleeding 5 (3.3) 7 (4.7) 0.55^
Severe hepatic disease 1 (0.7) 0 0.31^
Heparin induced thrombocytopenia 0 (0) 0 (0)
Current anticoagulation 41 (27.3) 38 (25.3) 0.69^
Other contraindication 0 (0) 2 (1.3) 0.15^
Percentages may not add up to 100 due to missing data. SD Standard Deviation; ^Chi-square.
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Table 4 Characteristics of the audited patients
Demographic Pre intervention (n = 150) Post intervention (n = 150) P Value
Age Mean (SD) 70.8 (14.4) 72.4 (13.9) 0.33*
Sex Number (%) 0.9^
Male 84 (56) 83 (55.3)
Female 66 (44) 67 (44.7)
Admitting specialty 0.98^
Cardiology 91 (61) 90 (60)
Oncology 3 (2) 3 (2)
Thoracic medicine 6 (4) 5 (3.3)
Gastroenterology 11 (7.3) 8 (5.3)
Nephrology 9 (6) 9 (6)
Neurology 13 (8.7) 12 (8)
Rheumatology 1 (0.3) 1 (0.3)
Cardiac investigations 12 (8) 18 (12)
Immunology 4 (2.7) 4 (2.7)
Percentages may not add up to 100 due to missing data. SD Standard Deviation; *T test; ^Chi-square.
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reported that the EOV was effective or extremely effect-
ive at increasing their knowledge and 15 (88%) felt that
it was effective or extremely effective at addressing their
concerns about VTE prophylaxis for medical patients.
The participants also agreed that the EOV was effective
at providing information on the four key messages
outlined in the study protocol: 16 (94%) participantsTable 5 Acceptability of the Educational Outreach Visit
How effective was the Educational Outreach Visit in…
Increasing or refreshing your knowledge about VTE prophylaxis
for medical patients?
Addressing concerns you have had about providing VTE prophylaxis
to medical patients?
Providing information about the significance of VTE as a healthcare issue?
Providing information about VTE risk assessment for medical patients?
Providing information about selecting appropriate VTE prophylaxis for
medical patients?
Providing information about the ongoing monitoring of patients risk
and response to prophylaxis?
How likely is it that… E
You will participate in another educational program such as this one
in the future?
This educational visit will influence your clinical practice?
What was the participants perceived level of…
Interest in the topic presented?
Participation during the visit?
Comprehension of the information provided?
Percentages may not add up to 100 due to missing data.reported that the EOV was effective or extremely effect-
ive at communicating the significance of VTE and the
importance of VTE risk assessment; 15 (88%) agreed
that the EOV was effective or extremely effective at pro-
viding information on selecting appropriate VTE
prophylaxis; and 10 (59%) felt that the EOV was effective
or extremely effective at providing information about
ongoing monitoring. When asked how likely it was thatExtremely
ineffective
Ineffective Unsure Effective Extremely
effective
n (%) n (%) n (%) n (%) n (%)
0 (0) 1 (5.3) 0 (0) 11 (58) 5 (26)
0 (0) 1 (5.3) 0 (0) 13 (68) 2 (11)
0 (0) 1 (5.3) 0 (0) 11 (58) 5 (26)
0 (0) 1 (5.3) 0 (0) 11 (58) 5 (26)
0 (0) 1 (5.3) 1 (5.3) 11 (58) 4 (21)
0 (0) 3 (16) 4 (21) 7 (37) 3 (16)
xtremely unlikely Unlikely Unsure Likely Extremely likely
1 (5.3) 0 (0) 3 (16) 11 (58) 2 (11)
1 (5.3) 0 (0) 3 (16) 11 (58) 2 (11)
Very low Low Average High Very high
2 (11) 3 (16) 3 (16) 6 (32) 5 (26)
1 (5.3) 1 (5.3) 4 (21) 3 (16) 10 (53)
0 (0) 0 (0) 2 (11) 7 (37) 10 (53)
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pants reported that it would be likely, or extremely likely.
The same number (n = 12, 71%) felt that the EOV was
likely, or extremely likely to influence their clinical prac-
tice. When the EOV facilitator was asked to rate the
participants’ (n = 19) perceived interest, participation and
comprehension in the EOV he reported that 11 (58%) par-
ticipants had a high or very high level of interest; 13 (68%)
had a high or very high level of participation; and 17 (89%)
had a high or very high level of comprehension.
Utility
Table 6 shows the descriptive data on the practical appli-
cation and utility of the intervention. The median num-
ber of times it was necessary to make contact with
participants to arrange the EOV was 3 (IQ range 1 to 4).
The median time spent on each EOV was 92 minutes
(IQ range 78 to 129) which was made up of time spent
arranging the EOV (median 10 minutes, IQ range 10 to
20); customising the material (median 45 minutes, IQ
range 45 to 60); waiting for the participant (median 5 mi-
nutes, IQ range 0–20) and conducting the EOV (median
15 minutes, IQ range 15 to 20). The majority of visits
were conducted in the doctor’s office (n = 10, 53%). The
remainder were held in the clinical area (n = 6, 32%);
other public area (n = 2, 10%); or other private area
(n = 1, 5%). At the completion of the EOV 15 (78%) of
the 19 participants gave a verbal commitment to provideTable 6 Utility of the educational outreach visit
Measures
Number of contacts needed to arrange the EOV
Number of contacts needed to arrange the visit
Number of cancelled visits prior to the visit
Time spent arranging and conducting the EOV (min)
Time spent arranging the visit
Time spent customising material
Time spent waiting for the participant
Time spent with the participant during the visit
Time spent on interruptions
Total time spent on the visit
Protocol adherence
Percent of protocol elements delivered to participant
Location of the EOV
Clinical area
Office
Other public area
Other private area
Outcome of the EOV
Participant agreed to provide evidence-based prophylaxis
IQ Interquartile.evidence-based prophylaxis. The facilitator’s self-reported
adherence to all of the elements of the EOV protocol was
80% (IQ range 70–85).
Clinical impact
There was a significant improvement in the proportion of
medical patients who received appropriate pharmacological
VTE prophylaxis following the intervention (54% to 70%,
16% improvement, 95% CI 5 to 26, p = 0.004). Removing
patients who were at lower risk of VTE from the analysis
made no difference to the significance of the result (47% to
63%, 16% improvement, 95% CI 3 to 27, p = 0.01).
Discussion
VTE is a major health and financial burden on the com-
munity [3]. Unfortunately, despite the availability of
evidence-based guidelines, VTE prophylaxis is still fre-
quently underutilised. Our study found that at baseline
only 54% of medical patients were receiving evidence-
based VTE prophylaxis. This confirms the evidence-
practice gap described in the international literature
[10-13]. Numerous strategies to improve VTE preven-
tion in hospitalised patients have been studied but none
have been successful at addressing all the barriers to the
provision of evidence-based care [15-19].
The barriers to the provision of appropriate medical
patient prophylaxis have been documented in a number
[27,28] of recent studies. Known barriers include a lackMedian (IQ range)
3 (1–4)
0
20 (10–20)
45 (45–60)
5 (0–20)
15 (15–20)
0
92 (78–129)
80 (70–85)
Number (%)
6 (32)
10 (53)
2 (10)
1 (5)
15 (79)
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of the presence of evidence-based guidelines; a lack of
knowledge on the indications for VTE prophylaxis and
on appropriate prophylaxis options; and a lack of agree-
ment and acceptance of current evidence-based recom-
mendations [27,28]. EOVs acknowledge and address
each participant’s barriers to change with the aim of fa-
cilitating increased compliance with evidence-based
practice [20]. Few studies have examined the clinical im-
pact of this intervention on the provision of VTE
prophylaxis to medical patients and no previous studies
have reported on its acceptability or utility.
Our results strongly suggest that EOVs are an accept-
able implementation strategy for doctors working in the
acute care setting. Nineteen (73%) of the 26 doctors eli-
gible to participate agreed to receive an EOV. This was a
greater than expected uptake given the established diffi-
culty in providing hospital delivered education to senior
doctors who, in the Australian private system, are con-
sultant practitioners and not employees of the hospital
[29]. It was also encouraging to find that following the
intervention 71% (n = 12) of participants who provided
feedback reported that they would participate in another
EOV in the future.
By reporting descriptive data on the practical applica-
tion and utility of the intervention we hope to provide
valuable information for anyone wishing to use this
intervention in an acute care hospital setting. Of particu-
lar note was the considerable time (92 minutes) required
to organise, prepare and deliver each EOV. This study is
one of a very few published studies to report the total
time required for each EOV and the only study set in an
acute care hospital setting.
Of the 19 participants who received the intervention
79% (n = 15) gave a verbal agreement to provide
evidence-based VTE prophylaxis to their medical pa-
tients. Importantly, this commitment translated into a
16% (95% CI 5 to 26, p = 0.004) improvement in prophy-
laxis rates above baseline. This clinical impact is much
larger than that reported in a Cochrane systematic re-
view on the effectiveness of EOVs [21]. The review
found that the median adjusted risk difference in com-
pliance with prescribing practices was only 4.8% (IQ
range 3.0% to 6.5%). The findings are similar, however,
to two previous studies which used EOVs to improve
doctors’ compliance with evidence-based VTE preven-
tion practices in the acute care hospital setting. Roberts
and Adams [25] observed a 14.2% (52.8% to 67%, p =
0.004) improvement in prophylaxis rates in medical pa-
tients while Grupper et al. [26] reported a 21% (29% to
50%, p < 0.001) improvement in a surgical population.
A limitation of our study was the use of a before-
and-after design which may be subject to methodological
limitations. There is some evidence to suggest thatuncontrolled before and after studies over-estimate the
effect of interventions [30]. Having only one post-
implementation data point collected three months after
the intervention means that we cannot know if the ob-
served improvement in practice will be sustained or im-
proved upon over time. The hospital plans to monitor
the sustainability of the improvement as part of the hos-
pitals ongoing quality systems. Future research is
recommended that examines the clinical impact of EOVs
on VTE prophylaxis using a cluster randomised con-
trolled trial which includes an evaluation of the ongoing
sustainability of the intervention.
Conclusion
This study confirms that EOVs are effective at improv-
ing doctors’ provision of pharmacological VTE prophy-
laxis to hospitalised medical patients. In addition, it
provides evidence of the acceptability of the interven-
tion as an implementation strategy in the acute care set-
ting, as well as valuable data on the practical application
and utility of EOVs for those wishing to use this inter-
vention in the future.
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